These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19373691)

  • 1. Emerging treatments for retinopathy of prematurity.
    Mantagos IS; Vanderveen DK; Smith LE
    Semin Ophthalmol; 2009; 24(2):82-6. PubMed ID: 19373691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinopathy of Prematurity: Therapeutic Strategies Based on Pathophysiology.
    Cayabyab R; Ramanathan R
    Neonatology; 2016; 109(4):369-76. PubMed ID: 27251645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinopathy of prematurity: current concepts in molecular pathogenesis.
    Heidary G; Vanderveen D; Smith LE
    Semin Ophthalmol; 2009; 24(2):77-81. PubMed ID: 19373690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
    Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Retinopathy of prematurity: from prevention to treatment].
    Daruich A; Bremond-Gignac D; Behar-Cohen F; Kermorvant E
    Med Sci (Paris); 2020 Oct; 36(10):900-907. PubMed ID: 33026333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.
    Eldweik L; Mantagos IS
    Semin Ophthalmol; 2016; 31(1-2):163-8. PubMed ID: 26959143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Retinopathy of prematurity - therapy. Part 2].
    Prepiaková Z; Tomčíková D; Kostolná B; Gerinec A
    Cesk Slov Oftalmol; 2014 Apr; 70(2):50-4. PubMed ID: 25030312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding retinopathy of prematurity: update on pathogenesis.
    Rivera JC; Sapieha P; Joyal JS; Duhamel F; Shao Z; Sitaras N; Picard E; Zhou E; Lachapelle P; Chemtob S
    Neonatology; 2011; 100(4):343-53. PubMed ID: 21968165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mediators involved in retinopathy of prematurity and emerging therapeutic targets.
    Mataftsi A; Dimitrakos SA; Adams GG
    Early Hum Dev; 2011 Oct; 87(10):683-90. PubMed ID: 21700404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of retinopathy of prematurity.
    Smith LE
    Semin Neonatol; 2003 Dec; 8(6):469-73. PubMed ID: 15001119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinopathy of prematurity.
    Jordan CO
    Pediatr Clin North Am; 2014 Jun; 61(3):567-77. PubMed ID: 24852153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in treatment of retinopathy of prematurity in the Netherlands from 2010 to 2017.
    Trzcionkowska K; Vehmeijer WBHJ; Kerkhoff FT; Bauer NJC; Bennebroek CAM; Dijk PH; Dijkman KP; van den Dungen FAM; Eggink CA; Feenstra RPG; Groenendaal F; van Heijst AF; van der Hoeven MAHBM; Kornelisse RF; Kraal-Biezen E; Lopriore E; Onland W; Renardel de Lavalette VW; van Rijn LJ; Schuerman FABA; Simonsz HJ; Voskuil-Kerkhof ESM; Witlox RSGM; Termote JUM; Schalij-Delfos NE
    Acta Ophthalmol; 2021 Feb; 99(1):97-103. PubMed ID: 32701185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinopathy of prematurity.
    Chen J; Smith LE
    Angiogenesis; 2007; 10(2):133-40. PubMed ID: 17332988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.
    Hartnett ME
    Clin Perinatol; 2014 Dec; 41(4):925-43. PubMed ID: 25459781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The German ROP Registry: data from 90 infants treated for retinopathy of prematurity.
    Walz JM; Bemme S; Pielen A; Aisenbrey S; Breuß H; Alex AF; Wagenfeld L; Schiedel S; Krohne TU; Stahl A;
    Acta Ophthalmol; 2016 Dec; 94(8):e744-e752. PubMed ID: 27197876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinopathy of prematurity: New developments bring concern and hope.
    Darlow BA
    J Paediatr Child Health; 2015 Aug; 51(8):765-70. PubMed ID: 25757043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment trends for retinopathy of prematurity in the UK: active surveillance study of infants at risk.
    Adams GG; Bunce C; Xing W; Butler L; Long V; Reddy A; Dahlmann-Noor AH
    BMJ Open; 2017 Mar; 7(3):e013366. PubMed ID: 28325857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Retinopathy of Prematurity - Update on Classification, Screening, and Therapy].
    Li JQ; Kellner U; Lorenz B; Stahl A; Krohne TU
    Klin Monbl Augenheilkd; 2022 Mar; 239(3):346-363. PubMed ID: 35253129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.